News & Updates
Filter by Specialty:
Nirmatrelvir conferred protection in older adults during the Omicron outbreak
During the surge of the Omicron (B.1.1.529) variant, antiviral therapy with nirmatrelvir significantly reduced the rate of COVID-19-related hospitalization or death among patients aged ≥65 years, according to a recent study.
Nirmatrelvir conferred protection in older adults during the Omicron outbreak
13 Sep 2022
Polypill strategy triumphs in reducing MACE post-MI
A polypill comprising aspirin, ramipril, and atorvastatin, significantly reduced the incidence of major adverse cardiovascular (CV) events in patents with a recent myocardial infarction (MI), according to results of a phase III trial presented at ESC 2022.
Polypill strategy triumphs in reducing MACE post-MI
12 Sep 2022
Patients upset by frequent side effects of RA drugs
Symptomatic adverse events (AEs) are common and troublesome for many patients with rheumatoid arthritis (RA) who are taking medications for their condition, results of an exploratory study have shown.
Patients upset by frequent side effects of RA drugs
12 Sep 2022
Add-on pyrotinib in neoadjuvant setting safe, effective for HER2-positive advanced breast cancer
In the treatment of patients with HER2-positive locally advanced breast cancer, adding pyrotinib to trastuzumab plus chemotherapy in the neoadjuvant setting yields high response rates while being safe, according to the results of NeoATP trial.
Add-on pyrotinib in neoadjuvant setting safe, effective for HER2-positive advanced breast cancer
12 Sep 2022
Antihypertensive drugs confer durable BP reduction in white-coat hypertension
Antihypertensive medications prove to be effective and lasting in decreasing office blood pressure (BP) among individuals with white-coat hypertension (WCH), suggests a study.
Antihypertensive drugs confer durable BP reduction in white-coat hypertension
11 Sep 2022
STRIDE regimen benefit in unresectable HCC consistent across baseline liver function
The overall survival (OS) benefit observed with the STRIDE regimen compared with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) is consistent regardless of baseline liver function, according to exploratory analysis of data from the phase III HIMALAYA trial presented at ESMO GI 2022.
